Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings

Suzanne Laplante (), Dilip U. Makhija (), Sibyl H. Munson (), Victor S. Khangulov (), Fred W. Peyerl (), Scott M. Paluszkiewicz (), Aditi J. Ravindranath () and Carol R. Schermer ()
Additional contact information
Dilip U. Makhija: Baxter Healthcare Corporation
Sibyl H. Munson: Boston Strategic Partners, Inc.
Victor S. Khangulov: Boston Strategic Partners, Inc.
Fred W. Peyerl: Boston Strategic Partners, Inc.
Scott M. Paluszkiewicz: Boston Strategic Partners, Inc.
Aditi J. Ravindranath: Boston Strategic Partners, Inc.
Carol R. Schermer: Advocate Medical Group

PharmacoEconomics - Open, 2018, vol. 2, issue 3, No 10, 325-335

Abstract: Abstract Background There is growing evidence of the benefits of intravenous fluid therapy with balanced crystalloids over 0.9% ‘normal’ saline. This analysis evaluated the economic impact of increasing usage of a calcium-free balanced crystalloid solution (BAL) in patients with systemic inflammatory response syndrome (SIRS) on an annual hospital budget. Methods An Excel®-based economic model was developed to estimate costs associated with increased BAL usage (i.e., use in a greater proportion of patients), from the US hospital perspective, over a 5-year time horizon. Clinical inputs were based on the results of a retrospective Electronic Health Record (EHR) database analysis identifying significantly fewer complications among SIRS patients receiving predominantly BAL versus saline. Complication-associated costs, adjusted to 2015, were obtained from published reports. Scenario analyses examined cost impacts for hospitals of various sizes, with different BAL adoption levels and rates. Results Base-case scenario analysis (300-bed hospital, 80% occupancy, current and year 5 BAL usage in 5 and 75% of SIRS patients, respectively, exponential year-over-year adoption) showed year 1 hospital savings of US$29,232 and cumulative 5-year savings of US$1.16M. Cumulative 5-year pharmacy savings were US$172,641. Scenario analyses demonstrated increasing cumulative 5-year savings with increasing hospital size, year 5 BAL usage in greater proportions of patients, and rapid/early BAL adoption. Conclusions Increased BAL usage represents an opportunity for hospitals and pharmacy departments to reduce complication-related costs associated with managing SIRS patients. The model suggests that savings could be expected across a range of scenarios, likely benefiting hospitals of various sizes and with different adoption capabilities.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0055-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:3:d:10.1007_s41669-017-0055-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0055-y

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().